Maritupirdine
Maritupirdine, a close structural analogue of latrepirdine, is a selective 5-HT6 receptor antagonist which is under development by Avineuro Pharmaceuticals for the treatment of Alzheimer's disease and anxiety disorders. As of November 2013, it was in phase II clinical trials for these indications.
It was approved in Russia on May 31, 2023 under the brand name Aviandr for the treatment of generalized [anxiety disorder], mild-to-moderate anxiety conditions and anxiety after COVID-19.